Table Of ContentAdvances in Experimental Medicine and Biology 1036
Pawel Kalinski Editor
Tumor Immune
Microenvironment
in Cancer
Progression and
Cancer Therapy
Advances in Experimental Medicine
and Biology
Volume 1036
Editorial Board:
IRUN R. COHEN, The Weizmann Institute of Science, Rehovot, Israel
ABEL LAJTHA, N.S.Kline Institute for Psychiatric Research,
Orangeburg, NY, USA
JOHN D. LAMBRIS, University of Pennsylvania, Philadelphia, PA, USA
RODOLFO PAOLETTI, University of Milan, Milan, Italy
NIMA REZAEI, Tehran University of Medical Sciences, Children’s Medical
Center Hospital, Tehran, Iran
More information about this series at http://www.springer.com/series/5584
Pawel Kalinski
Editor
Tumor Immune
Microenvironment
in Cancer Progression
and Cancer Therapy
Editor
Pawel Kalinski
Department of Medicine and Center
for Immunotherapy
Roswell Park Cancer Institute
Buffalo, NY, USA
ISSN 0065-2598 ISSN 2214-8019 (electronic)
Advances in Experimental Medicine and Biology
ISBN 978-3-319-67575-6 ISBN 978-3-319-67577-0 (eBook)
https://doi.org/10.1007/978-3-319-67577-0
Library of Congress Control Number: 2017960767
© Springer International Publishing AG 2017
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or
part of the material is concerned, specifically the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way,
and transmission or information storage and retrieval, electronic adaptation, computer software,
or by similar or dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a specific statement, that such names are
exempt from the relevant protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in
this book are believed to be true and accurate at the date of publication. Neither the publisher nor
the authors or the editors give a warranty, express or implied, with respect to the material
contained herein or for any errors or omissions that may have been made. The publisher remains
neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Printed on acid-free paper
This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Tumor microenvironment (TME) and the patterns of local interactions
between malignant cells, tumor stroma, and inflammatory infiltrate have been
extensively demonstrated to be essential for the survival of cancer cells, their
proliferation and invasion into surrounding tissues, and formation of distant
metastasis, as well as their resistance to treatments.
More recent works demonstrate that the immune component of the TME
(iTME) and the interactions between different types of immune cells, tumor-
associated fibroblasts, and cancer cells are critical for the success, and fre-
quent failure, of the spontaneously arising anticancer immunity and for the
effectiveness of different forms of immunotherapy. Most strikingly, recent
reports documented the critical role of the immune system and iTME in the
effectiveness of radio-and chemotherapy, the pillars of cancer treatment that
were traditionally considered as immunosuppressive, rather than
immunostimulatory.
This book Tumor Immune Microenvironment in Cancer Progression and
Cancer Therapy compiles 14 chapters discussing the roles of different iTME
components (cells, proteins, and nonprotein mediators) in tumor progression,
metastatic process, and different forms of cancer treatment, as well as newly
arising opportunities for their modulation to enhance the overall therapeutic
benefit of the comprehensive cancer care.
After decades of controversies regarding the role of immune system in
controlling cancer growth, fueled by frequent dissociation between the levels
of systemic immunity against tumor-related antigens (observed in the blood)
and cancer progression, recent clinical and animal studies have demonstrated
that the immune component of the TME is the key predictor of cancer pro-
gression and treatment outcomes. A striking example is the effectiveness of
checkpoint inhibitors, where the clinical responses and long-lasting therapeu-
tic benefit of individual patients, even patients with advanced cancer, can be
predicted by the levels of infiltration with cytotoxic T cells (CTLs) within the
TME. However, the current methods of evaluation of different iTME compo-
nents, and evaluating their intrinsic plasticity and context-dependent roles at
different stages of antitumor responses are not absolutely reliable. This war-
rants the development of new methods of TME analysis to optimally define
predictive markers and targets for cancer therapy.
v
vi Preface
I wholeheartedly thank all the authors, leaders in their respective fields,
who took time from their labs and other duties to share with you their insights
on different aspects of iTME during the progression of cancer and its
treatment.
I hope that you will find this book interesting, thought provoking, and
helpful in your research.
Buffalo, NY, USA Pawel Kalinski
Contents
1 Tumor Immuno-Environment in Cancer Progression
and Therapy ................................................................................... 1
Pawel Kalinski and James E. Talmadge
2 Cancer Immunotherapy Targets Based on Understanding
the T Cell-Inflamed Versus Non-T Cell- Inflamed Tumor
Microenvironment ......................................................................... 19
Thomas F. Gajewski, Leticia Corrales, Jason Williams,
Brendan Horton, Ayelet Sivan, and Stefani Spranger
3 Regulation of CTL Infiltration Within the Tumor
Microenvironment ......................................................................... 33
Sarah E. Church and Jérôme Galon
4 The Role of Tumor Microenvironment in Cancer
Immunotherapy ............................................................................. 51
Timothy Frankel, Mirna Perusina Lanfranca,
and Weiping Zou
5 Immunogenic and Non- immunogenic Cell Death
in the Tumor Microenvironment ................................................. 65
Jonathan M. Pitt, Guido Kroemer, and Laurence Zitvogel
6 Exosomes in Cancer: Another Mechanism of
Tumor-Induced Immune Suppression ........................................ 81
Theresa L. Whiteside
7 Chemo-Immunotherapy: Role of Indoleamine
2,3-Dioxygenase in Defining Immunogenic Versus
Tolerogenic Cell Death in the Tumor Microenvironment .......... 91
Theodore S. Johnson, Tracy Mcgaha,
and David H. Munn
8 Targeting Myeloid-Derived Suppressor Cells in Cancer ........... 105
Waseem Anani and Michael R. Shurin
vii
viii Contents
9 T ryptophan Catabolism and Cancer Immunotherapy
Targeting IDO Mediated Immune Suppression ......................... 129
Adaobi Amobi, Feng Qian, Amit A. Lugade,
and Kunle Odunsi
10 L ipid Inflammatory Mediators in Cancer Progression
and Therapy ................................................................................... 145
Saraswoti Khadge, John Graham Sharp,
Timothy R. McGuire, Geoffrey M. Thiele,
and James E. Talmadge
11 O ncolytic Virotherapy and the Tumor Microenvironment ....... 157
Sara E. Berkey, Steve H. Thorne, and David L. Bartlett
12 T he Impact of Housing Temperature-Induced Chronic
Stress on Preclinical Mouse Tumor Models and
Therapeutic Responses: An Important Role for the
Nervous System ............................................................................. 173
Bonnie L. Hylander, Jason W.-L. Eng,
and Elizabeth A. Repasky
13 Immunotherapeutic Targeting of Tumor-Associated
Blood Vessels .................................................................................. 191
Kellsye L. Fabian and Walter J. Storkus
14 A daptive Resistance to Cancer Immunotherapy ....................... 213
A.J. Robert McGray and Jonathan Bramson
15 Imaging the Tumor Microenvironment ....................................... 229
Marie-Caline Z. Abadjian, W. Barry Edwards,
and Carolyn J. Anderson
Index ....................................................................................................... 259
Contributors
Marie-Caline Z. Abadjian Department of Medicine, University of
Pittsburgh, Pittsburgh, PA, USA
Adaobi Amobi Department of Immunology, Roswell Park Cancer Institute,
Buffalo, NY, USA
Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA
Waseem Anani, M.D. Department of Pathology, University of Pittsburgh
Medical Center, Pittsburgh, PA, USA
Carolyn J. Anderson Department of Pharmacology & Chemical Biology,
University of Pittsburgh, Pittsburgh, PA, USA
Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA,
USA
W. Barry Edwards Department of Radiology, University of Pittsburgh,
Pittsburgh, PA, USA
Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA,
USA
David L. Bartlett Department of Surgery, University of Pittsburgh,
Pittsburgh, PA, USA
Sara E. Berkey Department of Surgery, University of Pittsburgh, Pittsburgh,
PA, USA
Jonathan Bramson, B.Sc., Ph.D. Department of Pathology and Molecular
Medicine, McMaster University, Hamilton, ON, Canada
Sarah E. Church Laboratory of Integrative Cancer Immunology, INSERM,
UMRS1138, Paris, France
Université Paris Descartes, Paris, France
Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris,
France
Leticia Corrales University of Chicago, Chicago, IL, USA
ix
